** Shares of hormonal disease-focused drug developer Crinetics CRNX.O rise 1.6% to $37.1 in premarket after TD Cowen starts coverage with a "buy" rating
** TD Cowen forecasts sales of $4 billion for co's experimental lead drugs by 2035
** Brokerage says market potential of co's once-daily pill paltusotine could be substantial, given similar drugs from Novartis NOVN.S and Ipsen IPN.PA collectively brought in $2.5 billion of sales in 2023
** Co is testing paltusotine to treat acromegaly, a condition in which excess growth hormone is produced, as well as carcinoid syndrome that causes symptoms from rare tumors
** CRNX is testing another drug, atumelnant, for a rare genetic disorder called congenital adrenal hyperplasia $(CAH)$ and Cushing's syndrome, a hormonal disorder
** "The company's success partly relies on its ability to obtain and maintain patent protection in the US and other countries for its product candidates," brokerage says
** Stock rose 44% in 2024
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.